<PAGE>
Total Number of Pages: 3
--
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: August 26, 1999
Commission File Number: 0-26208
================================================================================
KERAVISION, INC.
(Exact name of Registrant as specified in its Charter)
DELAWARE 77-0328942
(State of Incorporation) (I.R.S. Employer
Identification No.)
48630 MILMONT DRIVE
FREMONT, CA 94538
(Address of principal executive offices)
(510) 353-3000
(Registrant's telephone number)
<PAGE>
ITEM 5. OTHER EVENTS
On August 26, 1999, KeraVision, Inc. Appoints President & COO and VP-Sales.
Further details regarding this announcement are contained in the Comapny's news
release dated August 26, 1999 attached as exhibit hereto and incorporated
reference herein.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(a) Exhibits:
99.29 KeraVision, Inc. News Release dated August 26, 1999
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KERAVISION, INC.
/s/Mark Fischer-Colbrie
-----------------------
Mark Fischer-Colbrie
Vice President, Finance and
Administration and Chief Financial
Officer(Principal Financial and
Accounting Officer)
Date: August 26, 1999
3
<PAGE>
Exhibit 99.29
KeraVision Appoints President & COO and VP-Sales
Fremont, CA (August 26, 1999) -- KeraVision, Inc. (Nasdaq: KERA),
developer of Intacs (trademark) -- the first FDA-approved non-laser
option for surgically correcting myopia -- has appointed John Galantic
of SmithKline Beecham S.A. to the new position of KeraVision president
and chief operating officer.
Galantic, 37, who most recently served as SmithKline Beecham's Belgium
country manager, is credited with the successful European launch of
that company's smoking cessation brand, Niquitin, and for revitalizing
the over-the-counter franchise in Belgium with 17 percent annual growth
- -- the most of any consumer healthcare company in that market.
In addition, Steven M. Henderson, 40, sales director for Bausch &
Lomb's $50 million-a-year U.S. refractive surgery business and director
of training for more than 1,000 LASIK surgeons, has been named to the
new post of KeraVision vice president-sales.
KeraVision Chairman and Chief Executive Officer Thomas M. Loarie said,
"With these two key appointments, KeraVision has added to our skills in
consumer marketing and in professional development -- the two critical
sides to growing KeraVision's business."
Galantic joined SmithKline Beecham in 1994 as European director of
category management in the Consumer Healthcare Division where he was
responsible for such brands as Contac, Nicorette, Sucrets and
Beecham's. He rose to Belgium country manager in 1996 where he was
credited with turning around a flat business. Previously, Galantic was
European brand manager for Proctor & Gamble with marketing
responsibilities for $250 million in Vicks over-the-counter sales.
He holds a master's in business administration from Harvard Business
School and bachelor's degree from Tufts University.
Henderson joined Bausch & Lomb as U.S. field sales director in 1998
following that company's acquisition of Chiron Vision where he served
as national sales director, western region sales director and territory
manager starting in 1992. Previously, he was district sales manager
for Allergan Pharmaceuticals.
Henderson received a bachelor of science degree from Georgia Institute
of Technology.
KeraVision is developing a new category of non-laser vision correction
products for the treatment of common vision disorders, including myopia
(nearsightedness), hyperopia (farsightedness) and astigmatism, to offer
an alternative to eyeglasses, contact lenses and other vision
correction surgical procedures. KeraVision's first product, Intacs
corneal ring segments, has been approved by the FDA for correcting mild
myopia.
Except for the historical information, the matters discussed in this
news release are forward-looking statements. Actual results may differ
materially due to a variety of factors, including market acceptance of
KeraVision Intacs, complications relating to the product or the
surgical procedure, competitive products and technologies, and other
risk factors described under the heading "Risk Factors Affecting the
Company, Its Business and Its Stock Price" set forth in Form 10-Q for
the quarter ended June 30, 1999, and Form 10-K for the year ended
December 31, 1998, as well as in other SEC filings.
Note to Editors: Intacs are a registered trademark or trademark of
KeraVision, Inc. in the U.S. and foreign countries
Contact:
KeraVision, Inc., Fremont
Mark Fischer-Colbrie, 510/353-3000 (Investors)
Mick Taylor, 510/353-3075 (Media)
www.keravision.com
Fax on Demand, 800/448-8559
